References
- Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13:10–19.
- Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon. 1996;34:975–985.
- Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay.J Neural Transm. 2012;119:13–15.
- Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kD botulinum neurotoxin type A. Clin Neuropharmacol. 2009;32:28–31.
- Hunt T, Clarke K, Rupp D, Shimizu G, Weidler J. 50-U incobotulinumtoxinA drug product demonstrates lower potency when compared to 50-U onabotulinumtoxinA drug product with concurrent lower lightchain activity and atypical substrate cleavage. Presented at: 6th European Masters in Aesthetic & Anti-Aging Medicine (EMAA 2010), October 15–17, 2010, Paris, France.
- Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, . A multicenter, double-blind, randomised, placebo-controlled study of the efficacy, and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840–849.
- Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstruct Surg. 2003;112:1089–1098.
- Harii K, Kawashima M. A double-blind, randomised, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aes Plast Surg. 2008;32:724–730.
- Vistabel® Summary of Product Characteristics. Allergan, Inc, Germany, August 2010.
- Vistabel® Summary of Product Characteristics. United Kingdom. Available at: http://www.medicines.org.uk/emc/medicine/17580/SPC/vistabel/. Accessed August 25, 2011.
- Bocouture® Summary of Product Characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/23251/SPC/Bocouture/ Accessed August 25, 2011.
- Bocouture® Summary of Product Characteristics. Merz Pharmaceuticals GmbH, Germany, April, 2012.
- Moers-Carpi M. Comparison of the timeframe until first effect and the duration of action of two botulinum toxins in the forehead. Presented at: International Master Course on Aging Skin Conference, January 8–11, 2010, Paris, France.
- Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, . Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2011;36:2146–2154.
- Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?Dermatol Surg. 2007;33:S97–104.
- Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414–422; discussion 22.
- Mander G, Fink K, Vey M. Experimental conditions substantially influence botulinum toxin potency testing. Clin Neuropharmacol. 2009;32:234; author reply 35.
- Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003;31:265–276.
- Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm Ther. 2007;32:387–402.
- Wenzel RG. Biosimilars: illustration of scientific issues in two examples. Am J Health Syst Pharm. 2008;65:S9–15.
- Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, . Biosimilars—why terminology matters?Nat Biotechnol. 2011;29:690–693.